Trial reportThe pharmacogenomics journal2016
Genome-wide association study of leukotriene modifier response in asthma.
Trial report in The pharmacogenomics journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Differential connectivity of gene regulatory networks distinguishes corticosteroid response in asthma.The Journal of allergy and clinical immunology · 2018Trial
- Pharmacogenetics of childhood uncontrolled asthma.Expert review of clinical immunology · 2025Review
- Multi-omics in nasal epithelium reveals three axes of dysregulation for asthma risk in the African Diaspora populations.Nature communications · 2024Article
- Pharmacogenomics of Leukotriene Modifiers: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2022Article
- The Role of Innate Immunity and Bioactive Lipid Mediators in COVID-19 and Influenza.Frontiers in physiology · 2021Review
- Acute allergic rhinitis.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2020Article
- Review
- How does race and ethnicity effect the precision treatment of asthma?Expert review of precision medicine and drug development · 2019Article
- The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma.The pharmacogenomics journal · 2018Article
- Genetic Association Analysis of Fasting and 1- and 2-Hour Glucose Tolerance Test Data Using a Generalized Index of Dissimilarity Measure for the Korean Population.Genomics & informatics · 2016Article
- Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease.Immunology and allergy clinics of North America · 2016Review
- DNA methylation profiling in human lung tissue identifies genes associated with COPD.Epigenetics · 2016Article
- [Research advances in gene polymorphisms in biological pathways of drugs for asthma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016Review
- Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies.Frontiers in pharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Heterogeneous therapeutic responses to leukotriene modifiers (LTMs) are likely due to variation in patient genetics. Although prior candidate gene studies implicated multiple pharmacogenetic loci, to date, no genome-wide association study (GWAS) of LTM response was reported. In this study, DNA and phenotypic information from two placebo-controlled trials (total N=526) of zileuton response were interrogated. Using a gene-environment (G × E) GWAS model, we evaluated 12-week change in forced expiratory volume in 1 second (ΔFEV1) following LTM treatment. The top 50 single-nucleotide polymorphism associations were replicated in an independent zileuton treatment cohort, and two additional cohorts of montelukast response. In a combined analysis (discovery+replication), rs12436663 in MRPP3 achieved genome-wide significance (P=6.28 × 10(-08)); homozygous rs12436663 carriers showed a significant reduction in mean ΔFEV1 following zileuton treatment. In addition, rs517020 in GLT1D1 was associated with worsening responses to both montelukast and zileuton (combined P=1.25 × 10(-07)). These findings implicate previously unreported loci in determining therapeutic responsiveness to LTMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.